European experience on oncological outcomes of patients with early-stage non-small cell lung cancer and any prior cancer following lobectomy or segmentectomy

Lung, Respiratory and Thoracic Cancer

Disease characteristics and treatment outcomes in patients with resected early-stage ALK-positive non-small cell lung cancer from the randomized ALINA trial

Lung Cancer

Barlesi F, Ahn JS, Solomon BJ, Nishio M, Dziadziuszko R, Lee DH, Lee JS, Zhong W, Horinouchi H, Mao W, Hochmair M, de Marinis F, Migliorino MR, Bondarenko I, Xu T, Bara I, Ding B, Ngiam C, Petric P, Wu YL

doi: 10.1016/j.lungcan.2026.109385

Lung, Respiratory and Thoracic CancerCOVID-19

Treatment and outcomes of limited stage small cell lung cancer in the Canadian small cell lung cancer database (CASCADE)

Lung Cancer

Phillips WJ, Zhan LJ, Chowdhury D, Gill J, Sun A, Rittberg R, Cohen V, Gibson AJW, Yan M, Liwski D, Surapaneni S, D'Amours MF, Yu FPS, Kim Y, Qadeer RA, Dawe DE, Agulnik J, Navani V, Fung AS, Snow S, Kuruvilla S, Ho C, Lok BH, Liu G, Wheatley-Price P, Moore S

doi: 10.1016/j.lungcan.2025.108840

Lung, Respiratory and Thoracic Cancer

Definition of resectable stage III non-small cell lung cancer (NSCLC) for inclusion in clinical trials: A clinical case review by a pan-European multidisciplinary expert panel led by the EORTC Lung Cancer Group

Lung Cancer

Brandão M, Prisciandaro E, Xenophontos E, Mariolo A, Sadeghi AH, Filippi AR, Levy A, Bandura A, Caramella C, Dickhoff C, de Margerie-Mellon C, Faivre-Finn C, Portik D, Sanchez-Lorente D, De Ruysscher D, Smit E, Gobbini E, Fadel E, Ruffini E, Olmetto E, Cortiula F, Bahce I, Houda I, Opitz I, Naidoo J, Edwards J, Remon J, Benitez JC, Trujillo JC, Derks J, Amrane K, Hartemink KJ, Stathopoulos K, Hendriks LEL, Iglesias M, Occhipinti M, Guckenberger M, Giaj Levra N, Girard N, Reguart N, Mercier O, Bironzo P, Hofman P, Petersen RH, De Angelis R, Abgral R, Terrisse S, Popat S, Pierret T, Blum TG, Ricardi U, Dionisi V, Berghmans T, Dingemans AC, European Organisation for Research, Treatment of Cancer EORTC Lung Cancer Group

doi: 10.1016/j.lungcan.2025.108798

Lung, Respiratory and Thoracic Cancer

Mutation testing, treatment patterns, and outcomes in patients with unresectable stage III EGFR-mutated non-small cell lung cancer treated with chemoradiotherapy: Final analysis of a global real-world study

Lung Cancer

Ahn MJ, Lin SH, Yang CT, Lee JB, Neal JW, Okishio K, Nishino K, Smith D, Rauter M, Jimenez M, Nasirova F, Kim Y

doi: 10.1016/j.lungcan.2025.108748

Lung, Respiratory and Thoracic Cancer

Patient-reported outcomes from the LAURA study: osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer after definitive chemoradiotherapy

Eur J Cancer

Arriola E, Casarini I, Özgüroğlu M, Huang M, Takahashi T, Lai X, Goto K, Maneenil K, Lee KH, Cobo M, Valdiviezo N, Evans A, Bolanos A, Huang X, Lai R, Ramalingam SS

doi: 10.1016/j.ejca.2026.116744

Lung, Respiratory and Thoracic Cancer

Safety and outcomes of intensity modulated proton therapy in patients with non small cell lung cancer with interstitial lung disease

Lung Cancer

Roden RT, Harmsen WS, Breen WG, Moffett JN, Pulsipher SD, Olivier KR, Garces YI, Park SS, Merrell KW, Sarkaria JN, Owen D

doi: 10.1016/j.lungcan.2025.108789

Lung, Respiratory and Thoracic Cancer

Efficacy and safety of subcutaneous and intravenous administration of atezolizumab in patients with non-small cell lung cancer, including early-stage, locally advanced or metastatic disease: Updated results of the IMscin001 and IMscin002 randomized studies

Lung Cancer

Burotto M, Zvirbule Z, Alvarez R, Chewaskulyong B, Felip E, Majem M, Korbenfeld E, Kolb-Sielecki J, Isla D, Barata T, Bustillos A, Herraez-Baranda LA, Tosti N, Young F, Zanghi J, Cappuzzo F

doi: 10.1016/j.lungcan.2026.109452

Lung, Respiratory and Thoracic Cancer

Advanced-stage ALK-positive non-small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database

Lung Cancer

Reale ML, Scattolin D, Vitale A, Passiglia F, Grisanti S, Macerelli M, Galetta D, Sini C, Minuti G, Citarella F, Roca E, Agustoni F, Dodi A, Cortinovis D, Belluomini L, Ricciardi S, Veccia A, Pizzutilo EG, Scotti V, Alì G, Mazzoni F, Russo A, Pignataro D, Bulotta A, Piovano P, Sergi C, Bettini A, Genova C, Pavan A, Soto Parra HJ, Ortega C, Pozzessere D, Vavalà T, Chiari R, Zannori C, D'Aveni A, Meoni G, Giannarelli D, Malapelle U, Novello S, Bria E, Pasello G

doi: 10.1016/j.lungcan.2025.108762

Lung, Respiratory and Thoracic Cancer

Sex-specific efficacy and safety outcomes in patients with resectable stage III non-small-cell lung cancer (NSCLC) undergoing neoadjuvant therapies: a pooled analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14

ESMO Open

Frehner L, Schär S, Hayoz S, Guckenberger M, Finazzi T, Mark M, Addeo A, Mauti LA, Betticher D, Stupp R, Curioni-Fontecedro A, Peters S, Früh M, Rothschild SI, Pless M, König D, Opitz I, Ris HB, Özdemir BC, Schmid S

doi: 10.1016/j.esmoop.2025.105870

Related content

Disease characteristics and treatment outcomes in patients with resected early-stage ALK-positive non-small cell lung cancer from the randomized ALINA trial

Treatment and outcomes of limited stage small cell lung cancer in the Canadian small cell lung cancer database (CASCADE)

Definition of resectable stage III non-small cell lung cancer (NSCLC) for inclusion in clinical trials: A clinical case review by a pan-European multidisciplinary expert panel led by the EORTC Lung Cancer Group

Mutation testing, treatment patterns, and outcomes in patients with unresectable stage III EGFR-mutated non-small cell lung cancer treated with chemoradiotherapy: Final analysis of a global real-world study

Patient-reported outcomes from the LAURA study: osimertinib in patients with unresectable stage III EGFR-mutated non-small cell lung cancer after definitive chemoradiotherapy

Safety and outcomes of intensity modulated proton therapy in patients with non small cell lung cancer with interstitial lung disease

Efficacy and safety of subcutaneous and intravenous administration of atezolizumab in patients with non-small cell lung cancer, including early-stage, locally advanced or metastatic disease: Updated results of the IMscin001 and IMscin002 randomized studies

Advanced-stage ALK-positive non-small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database

Sex-specific efficacy and safety outcomes in patients with resectable stage III non-small-cell lung cancer (NSCLC) undergoing neoadjuvant therapies: a pooled analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14